Granulocyte and monocyte apheresis therapy for patients with active ulcerative colitis associated with COVID-19

被引：3

作者：

Koroku, Miki ^{[1
]}

Omori, Teppei ^{[1
]}

Kambayashi, Harutaka ^{[1
]}

Murasugi, Shun ^{[1
]}

Kuriyama, Tomoko ^{[1
]}

Ikarashi, Yuichi ^{[1
]}

Yonezawa, Maria ^{[1
]}

Arimura, Ken ^{[2
]}

Karasawa, Kazunori ^{[3
]}

Hanafusa, Norio ^{[4
]}

Kawana, Masatoshi ^{[5
]}

Tokushige, Katsutoshi ^{[1
]}

机构：

[1] Tokyo Womens Med Univ, Inst Gastroenterol, Tokyo, Japan

[2] Tokyo Womens Med Univ, Dept Resp Med, Tokyo, Japan

[3] Tokyo Womens Med Univ, Dept Med, Div Nephrol, Tokyo, Japan

[4] Tokyo Womens Med Univ, Dept Blood Purificat, Tokyo, Japan

[5] Tokyo Womens Med Univ, Primary Care Ctr, Tokyo, Japan

来源：

INTESTINAL RESEARCH | 2022年 / 20卷 / 01期

关键词：

COVID-19; Granulocyte and monocyte adsorptive apheresis; Ulcerative colitis; ADSORPTION APHERESIS; MANAGEMENT;

D O I：

10.5217/ir.2020.00148

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Coronavirus disease 2019 (COVID-19), caused by infection with severe acute respiratory syndrome coronavirus 2 (SARSCoV-2), is now a pandemic. Although several treatment guidelines have been proposed for patients who have both inflammatory bowel disease and COVID-19, immunosuppressive therapy is essentially not recommended, and the treatment options are limited. Even in the COVID-19 pandemic, adjuvant adsorptive granulocyte and monocyte apheresis may safely bring ulcerative colitis (UC) into remission by removing activated myeloid cells without the use of immunosuppressive therapy. Our patient was a 25-year-old Japanese male with UC and COVID-19. This is the first case report of the induction of UC remission with granulocyte and monocyte apheresis treatment for active UC associated with COVID-19. (Intest Res, Published online )

引用

页码：150 / 155

页数：6

共 20 条

[1] Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management (Publication with Expression of Concern)
Harbord, Marcus
Eliakim, Rami
Bettenworth, Dominik
Karmiris, Konstantinos
Katsanos, Konstantinos
Kopylov, Uri
Kucharzik, Torsten
Molnar, Tamas
Raine, Tim
Sebastian, Shaji
de Sousa, Helena Tavares
Dignass, Axel
Carbonnel, Franck
[J]. JOURNAL OF CROHNS & COLITIS, 2017, 11 (07) : 769 - 784
[2] Huang CL, 2020, LANCET, V395, P497, DOI [10.1016/S0140-6736(20)30211-7, 10.1016/S0140-6736(20)30183-5]
[3] COVID-19 cytokine storm: the interplay between inflammation and coagulation
Jose, Ricardo J.
Manuel, Ari
[J]. LANCET RESPIRATORY MEDICINE, 2020, 8 (06) : E46 - E47
[4] Adsorptive granulocyte and monocyte apheresis: A potentially relevant therapeutic option for COVID-19
Kanekura, Takuro
Kawahara, Koichi
[J]. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2020, 99 : 1 - 2
[5] Kappelman, SECURE IBD DATABASE
[6] Immunomodulatory effects of granulocyte and monocyte adsorption apheresis as a treatment for patients with ulcerative colitis
Kashiwagi, N
Sugimura, K
Koiwai, H
Yamamoto, H
Yoshikawa, T
Saniabadi, AR
Adachi, M
Shimoyama, T
[J]. DIGESTIVE DISEASES AND SCIENCES, 2002, 47 (06) : 1334 - 1341
[7] CYCLOSPORINE IN SEVERE ULCERATIVE-COLITIS REFRACTORY TO STEROID-THERAPY
LICHTIGER, S
PRESENT, DH
KORNBLUTH, A
GELERNT, I
BAUER, J
GALLER, G
MICHELASSI, F
HANAUER, S
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (26) : 1841 - 1845
[8] Inflammatory Bowel Disease Management During the COVID-19 Outbreak: The Ten Do's and Don'ts from the ECCO-COVID Taskforce
Magro, F.
Rahier, J-F
Abreu, C.
MacMahon, E.
Hart, A.
van der Woude, C. J.
Gordon, H.
Adamina, M.
Viget, N.
Vavricka, S.
Kucharzik, T.
Leone, S.
Siegmund, B.
Danese, S.
Peyrin-Biroulet, L.
[J]. JOURNAL OF CROHNS & COLITIS, 2020, 14 : S798 - S806
[9] Evidence-based clinical practice guidelines for inflammatory bowel disease
Matsuoka, Katsuyoshi
Kobayashi, Taku
Ueno, Fumiaki
Matsui, Toshiyuki
Hirai, Fumihito
Inoue, Nagamu
Kato, Jun
Kobayashi, Kenji
Kobayashi, Kiyonori
Koganei, Kazutaka
Kunisaki, Reiko
Motoya, Satoshi
Nagahori, Masakazu
Nakase, Hiroshi
Omata, Fumio
Saruta, Masayuki
Watanabe, Toshiaki
Tanaka, Toshiaki
Kanai, Takanori
Noguchi, Yoshinori
Takahashi, Ken-ichi
Watanabe, Kenji
Hibi, Toshifumi
Suzuki, Yasuo
Watanabe, Mamoru
Sugano, Kentaro
Shimosegawa, Tooru
[J]. JOURNAL OF GASTROENTEROLOGY, 2018, 53 (03) : 305 - 353
[10] Expert Opinions on the Current Therapeutic Management of Inflammatory Bowel Disease during the COVID-19 Pandemic: Japan IBD COVID-19 Taskforce, Intractable Diseases, the Health and Labor Sciences Research
Nakase, Hiroshi
Matsumoto, Takayuki
Matsuura, Minoru
Iijima, Hideki
Matsuoka, Katsuyoshi
Ohmiya, Naoki
Ishihara, Shunji
Hirai, Fumihito
Wagatsuma, Kouhei
Yokoyama, Yoshihiro
Hisamatsu, Tadakazu
[J]. DIGESTION, 2021, 102 (05) : 814 - 822

← 1 2 →